Essential Premium

Biopharma Hedge Funds Gain as Dealmaking Accelerates

“Many deals have targeted small- and midcap biotech companies advancing promising clinical programs, an area where we continue to find attractive investment opportunities,” says Andy Acker of Janus Henderson.

2026 FTF Fall Workshop

October 27-28, 2026 | The Langham

SpaceX Boosts Returns of Endowments That Invested Early

While MPI’s Michael Markov notes that “SpaceX can have an extraordinary impact on one year’s return,” that doesn’t necessarily tell us much about the long-term.

Sponsored

Think Your Pension Liability is Immune From AI-driven Market Dynamics? Think Again!

Why Flat Gold During Inflation Points to Fed Action

The Evolving Role of PE in Portfolios

Whale Rock Makes Rare VC Bet on Harvey at $15.5B Valuation

The value of the legal AI startup has climbed five-fold in 19 months, with fresh money from Whale Rock and continued support from Coatue.

Related Content

Affinity, Janus Henderson Outpace Biopharma Peers in Tough Month

Stephen Taub

Hamza Lemssouguer: If Your Credit Relies on Growth, Avoiding Disruption, and IPOs, It Looks a Lot Like Equity

Julie Segal

2026 TraderForum Equity Trading Summit

November 10-11, 2026 | Loews Coral Gables Hotel

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram